Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration
- PMID: 7646565
- DOI: 10.1016/0006-2952(95)00160-2
Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration
Abstract
In vivo stability and oral bioavailability of an oligodeoxynucleotide phosphorothioate containing segments of 2'-O-methyloligoribonucleotide phosphorothioates at both the 3'- and 5'-ends (hybrid oligonucleotide) were studied. A 25-mer 35S-labeled hybrid oligonucleotide was administered to rats by gavage at a dose of 50 mg/kg body weight. HPLC analysis revealed that this hybrid oligonucleotide was stable in the gastrointestinal tract for up to 6 hr following oral administration. Radioactivity associated with the hybrid oligonucleotide was detectable in portal venous plasma, systemic plasma, various tissues, and urine. Intact hybrid oligonucleotide was detected, by HPLC analysis, in portal venous plasma, systemic plasma, and various tissues. The majority of the radioactivity in urine was associated with degradative products with lower molecular weights, but the intact form was also detected. In summary, the hybrid oligonucleotide was absorbed intact through the gastrointestinal tract, indicating the possibility of oral administration of oligonucleotides, a finding that may be important in the development of antisense oligonucleotides as therapeutic agents.
Similar articles
-
In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats.Biochem Pharmacol. 1995 Aug 8;50(4):545-56. doi: 10.1016/0006-2952(95)00159-w. Biochem Pharmacol. 1995. PMID: 7646561
-
In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.Clin Chem. 1995 Jun;41(6 Pt 1):836-43. Clin Chem. 1995. PMID: 7768001
-
Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.Biochem Pharmacol. 1995 Mar 30;49(7):929-39. doi: 10.1016/0006-2952(95)00010-w. Biochem Pharmacol. 1995. PMID: 7741765
-
Pharmacokinetics of antisense oligonucleotides.Clin Pharmacokinet. 1995 Jan;28(1):7-16. doi: 10.2165/00003088-199528010-00002. Clin Pharmacokinet. 1995. PMID: 7712663 Review.
-
Pharmacokinetics of oligonucleotides.Ciba Found Symp. 1997;209:60-75; discussion 75-8. doi: 10.1002/9780470515396.ch6. Ciba Found Symp. 1997. PMID: 9383569 Review.
Cited by
-
Lipid nanoparticles for antisense oligonucleotide gene interference into brain border-associated macrophages.Front Mol Biosci. 2022 Nov 3;9:887678. doi: 10.3389/fmolb.2022.887678. eCollection 2022. Front Mol Biosci. 2022. PMID: 36406277 Free PMC article.
-
Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA.Mol Ther Nucleic Acids. 2017 Sep 15;8:158-168. doi: 10.1016/j.omtn.2017.06.012. Epub 2017 Jun 21. Mol Ther Nucleic Acids. 2017. PMID: 28918018 Free PMC article.
-
Assessment and comparison of thermal stability of phosphorothioate-DNA, DNA, RNA, 2'-F RNA, and LNA in the context of Phi29 pRNA 3WJ.RNA. 2018 Jan;24(1):67-76. doi: 10.1261/rna.063057.117. Epub 2017 Oct 19. RNA. 2018. PMID: 29051199 Free PMC article.
-
Metabolism, pharmacokinetics, tissue distribution, and stability studies of the prodrug analog of an anti-hepatitis B virus dinucleoside phosphorothioate.Drug Metab Dispos. 2012 May;40(5):970-81. doi: 10.1124/dmd.111.044446. Epub 2012 Feb 10. Drug Metab Dispos. 2012. PMID: 22328581 Free PMC article.
-
Hepatic distribution and clearance of antisense oligonucleotides in the isolated perfused rat liver.Pharm Res. 1997 Apr;14(4):516-21. doi: 10.1023/a:1012116003706. Pharm Res. 1997. PMID: 9144742
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous